Atreca, Inc.
BCELDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001532346
Atreca, Inc. was delisted in 2024; its insiders filed their last Form 4 on Apr 17, 2024; 43 institutions reported holding it in 13F filings for Q4 2023, worth $1.24M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Atreca, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Atreca, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Orwin John A | PRESIDENT & CEO | 1 | Apr 17, 2024 | 0 |
| Serafini Tito | Director | 43,636 | Apr 3, 2024 | 0 |
| Courtney Phillips | GENERAL COUNSEL & SECRETARY | 50,431 | Apr 3, 2024 | 0 |
| Baker Julian | Other: Former 10% Owner | 2,971,128Indirect | Oct 23, 2023 | 0 |
| Baker Felix | Other: Former 10% Owner | 2,971,128Indirect | Oct 23, 2023 | 0 |
| Baker Bros. Advisors LP | Other: Former 10% Owner | 2,971,128Indirect | Oct 23, 2023 | 0 |
| Baker Bros. Advisors (GP) LLC | Other: Former 10% Owner | 2,971,128Indirect | Oct 23, 2023 | 0 |
| Cross Herb | Chief Financial Officer | 72,817 | Aug 4, 2023 | 0 |
| Gould Stephen E | Chief Scientific Officer | 28,424 | Aug 4, 2023 | 0 |
| Ball Kristine M | Director | – | Jun 15, 2023 | 0 |
| Atwood Brian G | Director | – | Jun 15, 2023 | 0 |
| Berger Franklin M | Director | – | Jun 15, 2023 | 0 |
| Brady Stephen R | Director | – | Jun 15, 2023 | 0 |
| Rolfe Lindsey | Director | – | Jun 15, 2023 | 0 |
| Lacey David L. | Director | – | Jun 15, 2023 | 0 |
| Robinson William Hewitt | Director | – | Jun 15, 2023 | 0 |
| Ma Stacey | Director | – | Jun 15, 2023 | 0 |
| Bishop Philippe C | Chief Medical Officer | – | Jan 11, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2024 (view filing)7:36 PM ET | Apr 11 | 6 daysLate | Orwin John APRESIDENT & CEO | PPurchaseSeries A Junior Preferred Stock | +1 | $0.01 | +$0.01 | New position1 after | |
| Apr 3, 2024 (view filing)9:50 PM ET | Apr 1 | 2 days | Serafini TitoDirector | SSaleClass A Common Stock | −20.8K | $0.07 | −$1.46K | −32.3%43.6K after | |
| Apr 3, 2024 (view filing)9:37 PM ET | Sep 1, 2023 | 215 daysLate | Orwin John APRESIDENT & CEO | SSaleClass A Common Stock | −23.0K | $0.3746 | −$8.60K | −22.8%77.5K after | |
| Apr 3, 2024 (view filing)9:35 PM ET | Sep 1, 2023 | 215 daysLate | Serafini TitoDirector | SSaleClass A Common Stock | −8.39K | $0.3746 | −$3.14K | −11.5%64.4K after | |
| Apr 3, 2024 (view filing)9:33 PM ET | Sep 1, 2023 | 215 daysLate | Courtney PhillipsGENERAL COUNSEL & SECRETARY | SSaleClass A Common Stock | −7.06K | $0.3746 | −$2.65K | −12.3%50.4K after | |
| Oct 23, 2023 (view filing)4:49 PM ET | Oct 19 | 4 days | Baker Julian and 3 othersOther: Former 10% Owner | SSaleClass A common stock | −274.7K | $0.4025 | −$110.6K | −8.5%2.97M after | 2 lots |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Serafini TitoChief Strategy Officer | SSaleClass A Common Stock | −5.49K | $0.95 | −$5.21K | −7.0%72.8K after | |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Cross HerbChief Financial Officer | SSaleClass A Common Stock | −5.49K | $0.95 | −$5.21K | −7.0%72.8K after | |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Gould Stephen EChief Scientific Officer | SSaleClass A Common Stock | −4.08K | $0.95 | −$3.87K | −12.5%28.4K after | |
| Aug 4, 2023 (view filing) | Aug 2 | 2 days | Courtney PhillipsGeneral Counsel & Secretary | SSaleClass A Common Stock | −4.08K | $0.95 | −$3.87K | −6.6%57.5K after | |
| Sep 20, 2022 (view filing) | Sep 2 | 18 daysLate | Serafini TitoChief Strategy Officer | SSaleClass A Common Stock | −7.65K | $1.78 | −$13.6K | −18.1%34.6K after | |
| Sep 20, 2022 (view filing) | Sep 2 | 18 daysLate | Orwin John APresident & CEO | SSaleClass A Common Stock | −20.9K | $1.78 | −$37.2K | −17.2%100.5K after | |
| Sep 20, 2022 (view filing) | Sep 2 | 18 daysLate | Cross HerbChief Financial Officer | SSaleClass A Common Stock | −7.65K | $1.78 | −$13.6K | −18.1%34.6K after | |
| Sep 20, 2022 (view filing) | Sep 2 | 18 daysLate | Courtney PhillipsGeneral Counsel & Secretary | SSaleClass A Common Stock | −6.43K | $1.78 | −$11.4K | −18.1%29.1K after | |
| Jun 30, 2022 (view filing) | Jun 28 | 2 days | Serafini TitoChief Strategy Officer | SSaleClass A Common Stock | −15.0K | $2.02 | −$30.3K | −6.2%228.9K after | |
| Mar 8, 2022 (view filing) | Mar 4 | 4 days | Serafini TitoChief Strategy Officer | SSaleClass A Common Stock | −30.0K | $5.00 | −$150.0K | −11.0%243.9K after | |
| Sep 28, 2021 (view filing) | Sep 27 | 1 day | Serafini TitoChief Strategy Officer | SSaleClass A Common Stock | −30.0K | $6.58 | −$197.4K | −9.9%273.9K after |